Share on

Middle East And Africa High Throughput Screening Market Research Report - Segmented By Product, By Technology, By Application, By End User & By Country(KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) -Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2023 to 2028)

Published: March, 2023
ID: 6293
Pages: 145
Formats: report pdf report excel report power bi report ppt

MEA High Throughput Screening Market Size (2023 to 2028)

The size of the high throughput screening market in the Middle East and Africa is anticipated to grow at 6.9% CAGR from 2023 to 2028, and it is estimated that the Middle East and Africa market was valued at USD 1.48 billion in 2023 and is expected to reach USD 2.07 billion by 2028.

The rise in the number of potential drug targets and advancements in technologies leading to the emergence of innovative technologies and platforms like analytical tools that deal with massive amounts of data drive market growth. In addition, growth in demand for high throughput screening devices in stem cell research for assessing excretion, metabolism, distribution, and absorption characteristics and investigation of functional activity are significant drivers of the MEA high throughput screening market. Also, the availability of government funding, collaborations of research, and academic institutions with pharmaceutical industries for developing innovative ways for drug delivery are further catalyzing the growth of the MEA high throughput screening market.

The factors that provide growth opportunities for expanding the high throughput screening market during the forecast period are the evolution of preclinical drug development and discovery systems by adopting human stem cell-based high throughput screenings and assays. Emerging economies of countries are increasing the market's growth opportunities due to rapid growth in pharmaceutical industries and the integration of innovative technologies, a significant push for research by governments of these countries in the life sciences industry.

Restraints challenging the growth of the high throughput screening market are costs, the requirement of extensive automation techniques, the capital-intensive nature, and budget restrictions for academic research purposes. There is an increased requirement for instruments in biotechnological and pharmacy companies, resulting in a notable rise in these companies' capital costs that are expected to limit the MEA high throughput screening market during the forecast period.

This research report on the MEA high throughput screening market has been segmented and sub-segmented into the following categories:

By Product:

  • Consumables And Reagents
  • Instruments
  • Software And Services

By Technology: 

  • Cell-based Assays
  • Lab-on-a-chip
  • Ultra-High-Throughput Screening
  • Label-Free Technology
  • Bioinformatics

By Application:

  • Target Identification
  • Primary Screening
  • Toxicology
  • Others

By End User: 

  • Pharmaceutical and Biotechnology Companies
  • Academic and Government Research Institutes
  • Contract Research Organizations
  • Other End Users

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Regionally, South Africa and Saudi Arabia witnessed to grow with the highest CAGR in the MEA high throughput screening market during the forecast period. Technological advancements in high throughput growing pharmaceutical research and development expenses are likely to fuel the market growth during the historical period. In addition, the availability of funds from the government integrated with developing common diseases is propelling the market.

Other countries like UAE, Ethiopia, Israel, Sudan, Kenya, Egypt, and the rest of the MEA are expected to grow in the region's market.

KEY MARKET PARTICIPANTS:

Agilent Technologies Inc., Danaher Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Tecan Group Ltd., Millipore, Bio-Rad Laboratories, Hamilton Company, Axxam S.p.A., and Aurora Biomed are some of the notable companies in the MEA high throughput screening market.

Please wait. . . . Your request is being processed

FAQ's

What is the growth rate of the MEA high throughput screening market?

The MEA high throughput screening market is expected to grow at a CAGR of 6.9% from 2022 to 2027.

Who are the key players in the MEA high throughput screening market?

Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Merck KGaA are some of the notable companies in the MEA high throughput screening market.

What are the key factors driving the growth of the MEA high throughput screening market?

Factors such as the growing prevalence of chronic diseases, growing demand for personalized medicine, and advancements in technology that enable more efficient and cost-effective screening are propelling the MEA high throughput screening market. 

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample